Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05992623 · ClinicalTrials.gov registry record · NA
Clinical Trial Comparing Devices Used for Cardioversion of Atrial Fibrillation
A NA study of Atrial Fibrillation, sponsored by Inova Health Care Services.
- Completed
- Registry status
- NA
- Development phase
- 546
- Enrollment target
- 1
- Study location
NCT05992623: Completed NA study of Atrial Fibrillation, sponsored by Inova Health Care Services.
NCT05992623 is a NA study of Atrial Fibrillation that has completed, run by Inova Health Care Services. The registered enrollment target is 546 participants, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05992623, a NA study of Atrial Fibrillation, has completed, sponsored by Inova Health Care Services.
- COMPLETED
- Registry status
- NA
- Development phase
- 546 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this single center, investigator initiated, open label prospective randomized controlled trial is to compare the efficacy of a single 200J RBW shock and a single 360J BTE shock. The secondary objective of the study is to compare the frequency of adverse events after one or two 200J RBW or 360J BTE shocks
Primary Outcome
The frequency of NSR by ECG one minute after a single full output DCCV shock is delivered by either a 200J RBW waveform shock from a Zoll Series R defibrillator or 360J BTE waveform shock from a Lifepak 15 defibrillator
Conditions Studied
Interventions
- DEVICE Zoll external defibrillator
- DEVICE Lifepak external defibrillator
Study Locations (1)
Virginia
- Inova Health System - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 546 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2024-12-11 |
| Phase | NA |
What the finished NCT05992623 record still lists
NCT05992623 is an interventional study that assigns participants to a tested intervention. The registered 546 participants enrollment target is mid-sized for trials with a published cap, below the 2,994-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Zoll external defibrillator is the first listed.
NCT05992623 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT05992623 about?
NCT05992623 is a clinical study titled "Clinical Trial Comparing Devices Used for Cardioversion of Atrial Fibrillation". The goal of this single center, investigator initiated, open label prospective randomized controlled trial is to compare the efficacy of a single 200J RBW shock and a single 360J BTE shock. The secondary objective of the study is to compare the frequency of adverse events after one or two 200J RBW o...
What is the current status of trial NCT05992623?
This trial is currently completed. It is a NA study. The enrollment target is 546 participants. The study started on 2023-07-21. Estimated completion is 2024-12-11.
What conditions does trial NCT05992623 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT05992623?
The interventions under investigation include: Zoll external defibrillator (DEVICE), Lifepak external defibrillator (DEVICE).
Who is sponsoring clinical trial NCT05992623?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05992623 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05992623's enrollment target sits among peer trials
546 57th of 202 higher than 146 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
-
The CONFORM Pivotal Trial
RECRUITING · NA
-
Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study
RECRUITING · NA
-
The Fourth Left Atrial Appendage Occlusion Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03572374 · 546 participants · NA
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
- NCT05937685 · 546 participants · NA
Reducing Blood Pressure in Patients With High Cardiovascular Risk
- NCT06416150 · 546 participants · NA
Reducing Urban Cervical Cancer Disparities
- NCT06850922 · 546 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI